Key Highlights

  • Onconetix (NASDAQ:ONCO) was trading 32.24% higher at USD 7.26 on Friday, November 6, 2026, and no company announcement for that day turned up.
  • In February 2026 the company agreed to take all of humanoid robot maker Realbotix in an all-stock exchange, with the closing aimed at the second half of 2026.
  • Shares had undergone a 1-for-5 reverse split effective March 25, 2026, and on October 22 they closed at USD 0.41, just above a 52-week low of USD 0.38.
  • Over 52 weeks the shares moved between USD 0.38 and USD 200.00, and Market Value sat around USD 1.78 million at the October 22 price on one published page.

A 32.24% Advance Lacks a Dated Announcement

Onconetix (NASDAQ:ONCO) was trading 32.24% higher at USD 7.26 on Friday, November 6, 2026. Company releases and filings dated between November 3 and November 6, 2026 were not found that would explain the rise. Working backward from the quote gives a prior close near USD 5.49, a calculated figure. The USD 0.41 close logged on October 22, 2026 is far lower, which suggests an unverified reverse split or share adjustment, so older prices deserve caution. Anyone comparing today's quote with earlier prints may be working from figures on different share bases.

Realbotix Purchase Terms and Bridge Funding

The main story is the pending purchase of Realbotix, a company developing AI-powered humanoid robots. Onconetix entered a definitive share exchange agreement in mid-February 2026 covering all of Realbotix, paid entirely in stock. On a fully diluted basis, Realbotix shareholders should hold most of the merged company, and the final ratio hinges on how much net cash Onconetix holds at closing. The deal is aimed to close in the back half of 2026. Earlier, in September 2026, Onconetix supplied bridge funding to Realbotix, and a September 24 release noted that SRX Global, an Investment firm, had taken a stake in Onconetix. Realbotix also disclosed that its Vinci AI vision system reached Ericsson in April, and a telecom pilot in Europe used humanoid robots at live events in September. Such items reflect the target's operations, not Onconetix's own results, and no Revenue figures for the combined Business were located.

Dilution, Listing Notices and Why Quoted Moves Reverse

Because the deal is paid in stock, today's holders could end up owning a small slice of the combined company, and the final split was not disclosed in the material reviewed. Several filings describe notices about delisting or failure to meet a listing rule, though their dates and specifics were not confirmed here. Keeping the listing matters for the deal, since the merged company would need a tradable security for Realbotix holders. By October 22 the Equity had dropped roughly 37.8% across two weeks and nearly 99.8% across twelve months, as shown on an online market-data listing. At a market value in the low millions, a few trades can jolt the quote, bid-ask gaps may be wide and the moves may flip.

Where Things Stand

The 32.24% gain is not linked to any dated announcement that was located. Onconetix (NASDAQ:ONCO) is shifting toward humanoid robotics via a pending deal paid in shares for Realbotix, and earlier spikes in the shares have been tied to speculation about that transaction. Heavy dilution, listing compliance, split-related distortion of the price history and thin trading make up the risk set. Upcoming checkpoints include when the Realbotix transaction closes, whether new funding arrives and what Nasdaq letters, if any, come in.